Innovation enabled Germany’s Stada Arzneimittel’s Consumer Healthcare business to secure continued growth in 2024 despite a weak cough and cold season, according to the firm’s latest financial results.
Stada’s CHC sales increased organically by 3% to €1.54bn in the 12 months up to 31 December 2024, the firm reported
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?